Mergers & Acquisitions Mergers & Acquisitions

Pharmacy benefit managers’ incentives to self-preference, engage in exclusionary rebates warrant more scrutiny, US FTC says

By Khushita Vasant
  • 09 Jul 2024 13:45
  • 09 Jul 2024 16:39
Concentration among pharmacy benefit managers is increasing, with vertical integration having raised various competitive concerns in the drug supply chain in the US as well as financial conflicts of interest which should be investigated further, the Federal Trade Commission said today.
The FTC published a 73-page interim staff report on

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US

Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News